Search

Displaying results 851 - 860 of 1237 in total
  1. Drug

    Telapristone acetate

    go.drugbank.com/drugs/DB05253
    Investigational

    Telapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.

  2. Drug

    Collagen-polyvinylpyrrolidone

    go.drugbank.com/drugs/DB16525
    Investigational

    Collagen-polyvinylpyrrolidone is a copolymer generated from a mixture of type I collagen and low-molecular-weight PVP that has undergone γ irradiation[A227733].

  3. Drug

    Pixatimod

    go.drugbank.com/drugs/DB19166
    Investigational

    Pixatimod is under investigation in clinical trial NCT05061017 (Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide

  4. Drug

    Carbenoxolone

    go.drugbank.com/drugs/DB02329
    Experimental

    Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity. [PubChem]

  5. Drug

    Elesclomol

    go.drugbank.com/drugs/DB05719
    Investigational

    Elesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death. In preclinical models elesclomol showed potent killing of a broad r...

  6. Drug

    G4544

    go.drugbank.com/drugs/DB05244
    Experimental

    G4544 is an oral gallium compound that enables oral absorption of the active ingredient contained in Ganite™ (gallium nitrate injection). It targets bone tissue and is actively incorporated into bone mineral at sites where bone is metabo...

  7. Drug

    ZEN-012

    go.drugbank.com/drugs/DB06042
    Experimental

    ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti...

  8. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    The binding of IGF-1 to IGFBP-3 is said to extend the half life and reduce the clearance of IGF-1 in patients with growth hormone resistant syndromes and low levels of IGFBP-3 though this may represent

  9. Drug

    Pegloticase

    go.drugbank.com/drugs/DB09208
    ApprovedInvestigational

    Therefore therapeutic drug levels can be maintained with infrequent and relatively low pegloticase doses.[A249980] The PEG group also gives pegloticase a lower potential to induce an immune response.

  10. Drug

    Ketamine

    go.drugbank.com/drugs/DB01221
    ApprovedInvestigationalVet approved

    Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Be...